Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study From the SFGM-TC

• Published in: Journal of clinical oncology Vol. 26; no. 30; pp. 4940 - 4943
• Main Authors: CHEVALLIER, Patrice, MOHTY, Mohamad, BLAISE, Didier, TABRIZI, Reza, BUZYN, Agnes, SOCIE, Gerard, MICHALLET, Mauricette, VOLTEAU, Christelle, HAROUSSEAU, Jean-Luc, LIOURE, Bruno, MICHEL, Gerard, CONTENTIN, Nathalie, DECONINCK, Eric, BORDIGONI, Pierre, VERNANT, Jean-Paul, HUNAULT, Mathilde, VIGOUROUX, Stéphane
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 20.10.2008; Lippincott Williams & Wilkins
• Subjects: Adolescent; Adult; Biological and medical sciences; Child; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunology; Life Sciences; Male; Medical sciences; Middle Aged; Retrospective Studies; Sarcoma, Myeloid; Sarcoma, Myeloid - mortality; Sarcoma, Myeloid - therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome; Tumors; Cancerology; Sarcoma; Stem cell; Hematopoietic cell; Homograft; Graft; Malignant tumor; Retrospective; Cancer
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2007.15.6315

This retrospective multicenter study assessed the outcome of 51 patients with myeloid sarcoma (MS) who underwent allogeneic hematopoietic stem-cell transplantation (alloHSCT). Most patients had MS presenting in conjunction with acute myeloid leukemia (AML) or after AML. Six patients had isolated MS. The median time between diagnosis and alloHSCT was 8 months (range, 2.8 to 67). Forty patients were in complete remission (CR) at time of alloHSCT. With a median follow-up of 33 (range, 1 to 182) months, the Kaplan-Meier estimates of overall survival (OS) and disease-free survival were 47% (95% CI, 33% to 61%) and 36% (95% CI, 24% to 50%) at 5 years. Twenty patients (39%) relapsed at a median of 204 (range, 35 to 1151) days after alloHSCT, with relapse being the major cause of death. In a Cox multivariate analysis, age > or = 15 years and remission status at time of alloHSCT (CR v other) were associated with improved OS (hazard ratio [HR], 0.27; 95% CI, 0.12 to 0.65; P = .003; and HR, 0.22; 95% CI, 0.08 to 0.57; P = .002, respectively). We conclude that first-line alloHSCT performed early in the course of MS is a valid therapeutic option.